Could a diabetes drug boost psoriasis treatment in overweight patients?
NCT ID NCT07485764
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests whether adding metformin (a diabetes drug) to the standard psoriasis treatment secukinumab works better than secukinumab alone for overweight or obese Chinese patients with moderate-to-severe plaque psoriasis. About 186 participants will be randomly assigned to receive either the combination or secukinumab plus a placebo. The main goal is to see if more patients achieve clear or almost clear skin after 24 weeks.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE TO SEVERE PLAQUE PSORIASIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Once-Weekly pill clear stubborn psoriasis?
- Can patients power their own obesity research?
- Can a new injection clear psoriasis when other biologics fail?
- Can a gel tame psoriasis? new antibody fragment put to the test
- Can a new gel calm psoriasis Flare-Ups?
- Can a Once-Daily cream tame psoriasis in toddlers?